About Eyegenex
Eyegenex is a Healthcare company based in San Diego (United States) founded in 2023. Gene therapies for ophthalmic disorders, including glaucoma, are developed. Eyegenex has raised $745 thousand across 1 funding round from investors including Newsight Tech Angels and NuFund. Eyegenex offers products and services including Glaucoma Treatment Drug, Diabetic Retinopathy Therapeutic, and NAION Treatment Drug. Its focus areas include Life Sciences, Ophthalmology, Drugs and Glaucoma. Its competitors include Qlaris Bio, TearClear and Aria Pharmaceuticals; 3 of its 3 listed competitors have raised funding.
Company details
Eyegenex was founded in 2023 in San Diego, United States. Gene therapies targeting ophthalmic disorders are developed by the company within the biotechnology sector. Focus is placed on treatments for glaucoma to address vision loss and prevent blindness. Operations involve research and development of these therapies, with activities centered in the United States to support clinical advancements in eye care.
- Headquarters San Diego, United States
- SectorsHealthcare
- Email••••••••
- Website eyegenex.com
- Total Equity Funding$745K (USD)
in 1 rounds
- Latest Funding Round$745K (USD), Seed
Sep 2023
- InvestorsNewsight Tech Angels
& 1 more
Products & Services of Eyegenex
Eyegenex offers a comprehensive portfolio of products and services, including Glaucoma Treatment Drug, Diabetic Retinopathy Therapeutic, and NAION Treatment Drug.
Drug designed to reduce visual loss in Glaucoma patients through proven animal studies.
Therapeutic targeting blood vessel damage in Diabetic Retinopathy for vision preservation.
Drug for treating NAION to prevent progressive visual loss in affected individuals.
Funding Insights of Eyegenex
Eyegenex has successfully raised a total of $745K through 1 strategic funding round. The most recent funding activity was a Seed round of $745 thousand completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $745,000
- Total Rounds 1
- Last Round Seed — $745,000
- First Round $745,000
(Sep 2023)
- Investors Count 2
All 1 funding rounds of Eyegenex with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2023 | $745,000 | Seed | – | Newsight Tech Angels, NuFund | – |
2 investors in total: 2 institutional.
Investors in Eyegenex
Eyegenex has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Newsight Tech Angels and NuFund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment in biotechnology and healthcare startups is facilitated. | ntangels.com | Japan | ||
Technology sectors are invested in by NuFund venture capital firm. | nufund.com | San Diego, United States |
Investor details for Eyegenex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Eyegenex
2 dated milestones of Eyegenex, from founding to its latest funding, stage changes and deals.
- Founded Eyegenex is founded.
- Funding First funding round of $745K.
Competitors of Eyegenex
Eyegenex has 3 listed competitors in our database, 3 of them funded. They include Qlaris Bio, TearClear and Aria Pharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| qlaris.bio | 2019 | United States | $49.03M | AI-based technology is developed for treating ophthalmic diseases. | ||
| tearclear.com | 2015 | Copley Township, United States | $31.98M | Filter technology for preservative-free ophthalmic drugs is developed. | ||
| ariapharmaceuticals.com | 2015 | Palo Alto, United States | $14.31M | Develops innovative drug technologies for multiple diseases. |
Detailed competitors of Eyegenex
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
3 companies that operate in the same segment as Eyegenex (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Eyegenex
Eyegenex was founded in 2023.
Eyegenex is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Eyegenex is a funded company, having raised a total of $745K across 1 funding round to date. The company's 1st funding round was a Seed of $745K, raised on Sep 2023.
Eyegenex was founded in 2023 in San Diego, United States. Gene therapies targeting ophthalmic disorders are developed by the company within the biotechnology sector. Focus is placed on treatments for glaucoma to address vision loss and prevent blindness. Operations involve research and development of these therapies, with activities centered in the United States to support clinical advancements in eye care.
Eyegenex's top competitors include Qlaris Bio, TearClear and Aria Pharmaceuticals.
Eyegenex offers Glaucoma Treatment Drug, Diabetic Retinopathy Therapeutic, and NAION Treatment Drug.
Eyegenex has 2 investors. Key investors include Newsight Tech Angels, and NuFund.